Facial Palsy: Upper vs Lower Motor Neuron Lesions | Clinical Guide

Brainstem syndromes are classified by anatomical location (midbrain, pons, medulla) and involve specific combinations of cranial nerve nuclei, motor tracts, and sensory pathways, producing characteristic clinical patterns that allow precise localization of lesions; for example, Weber syndrome (midbrain ventral) involves CN III nucleus with corticospinal tract causing ipsilateral third nerve palsy and contralateral hemiplegia, while Millard-Gubler syndrome (pons ventral) involves facial nucleus and abducens nucleus causing ipsilateral facial palsy and contralateral hemiplegia, and Wallenberg syndrome (medulla lateral) involves vestibular nucleus, spinal trigeminal nucleus, and lateral spinothalamic tract causing ipsilateral ataxia, facial sensory loss, and contralateral pain/temperature loss.

The brainstem contains cranial nerve nuclei organized into columns: general somatic efferent (GSE) for third, fourth, sixth, and twelfth nerves; special visceral efferent (SVE) for fifth, seventh, ninth, tenth, and eleventh nerves; general visceral efferent (GVE) for third, seventh, ninth, and tenth nerves; and general visceral afferent (GVA) and special visceral afferent (SVA) for ninth and tenth nerves. The ventral brainstem shows midbrain with cerebral peduncles and interpeduncular fossa (third nerve emerges), pons with basis pontis and olives (sixth, seventh, eighth nerves emerge), and medulla with pyramids and olives (ninth, tenth, eleventh, twelfth nerves emerge). The dorsal brainstem floor of the fourth ventricle shows sulcus limitans dividing alar (sensory) and basal (motor) plates. Brainstem syndromes help localize lesions: Weber syndrome (midbrain) involves third nerve palsy, contralateral hemiplegia, and contralateral facial weakness; Millard-Gubler syndrome (pons) involves sixth and seventh nerve palsies with contralateral hemiplegia; medial medullary syndrome (Dejerine) involves contralateral hemiplegia, contralateral loss of proprioception, and ipsilateral tongue paralysis; lateral medullary syndrome (Wallenberg) involves ipsilateral facial pain/temperature loss, contralateral body pain/temperature loss, and ipsilateral bulbar paralysis.

Facial nerve lesions are localized by level: upper motor neuron lesions (cortical) spare the upper face; lower motor neuron lesions from the nucleus (pontine stroke) affect the entire face; lesions at the internal auditory meatus (schwannomas); lesions at the stylomastoid foramen or parotid gland (tumors); Ramsay Hunt syndrome (herpes zoster oticus). Bell's palsy is idiopathic but now associated with herpes simplex virus. Non-isolated syndromes include combinations like facial nerve palsy with abducens nerve palsy, localizing to the facial colliculus where the facial nerve loops around the abducens nucleus.

This extensive section covers the major pontine lesion syndromes based on lesion location. Ventral pontine syndrome (Millard-Gubler) involves facial nerve, abducens nerve, and corticospinal fibers, producing ipsilateral facial palsy, lateral rectus palsy, and contralateral hemiplegia. Fovale syndrome adds paramedian pontine reticular formation involvement, causing ipsilateral gaze palsy. Ventromedial pontine syndrome (Raymond) affects only facial nerve and corticospinal fibers. Lateral pontine syndrome (Marie) involves spinal lemniscus (causing contralateral sensory loss) and middle cerebellar peduncles (causing ipsilateral cerebellar ataxia). Each syndrome demonstrates how specific brainstem structures produce characteristic clinical patterns when damaged.

Ventral pontine syndrome, also known as Millard-Gubler syndrome, is a neurological condition affecting the ventral portion of the pons, characterized by a triad of ipsilateral facial palsy (due to facial nerve nucleus involvement), ipsilateral lateral rectus palsy (due to abducent nerve nucleus involvement), and contralateral hemiplegia (due to corticospinal tract involvement), commonly caused by tumors, stroke, demyelination, or infection in the ventral pons.

Bell's palsy is differentiated from stroke by asking patients to raise eyebrows and wrinkle forehead - symmetrical wrinkling suggests stroke, asymmetrical wrinkling with inability to close eye tightly suggests Bell's palsy. Bell's palsy grading: Grade 1-3 (mild-moderate weakness), Grade 4-5 (obvious asymmetry), Grade 6 (total paralysis). Treatment should begin within 72 hours for best prognosis. Protocol: prednisone 60mg/day for 5 days, then taper by 10mg daily (days 6-10). Use methylprednisolone 4mg = prednisone 5mg. Add vitamin B12. For Grade 4-5, add acyclovir 400mg 5x daily. Complications include eye issues (keratitis, corneal ulcer) requiring eye drops during day, eye ointment at night, and eye patching. Referral criteria: vesicles in ear canal (Ramsay Hunt syndrome), hearing loss with vertigo, no improvement after 2-3 weeks, or uncertainty about stroke vs. Bell's palsy.

Bell's palsy is a benign, self-limiting condition with good prognosis, but patients often seek emergency care due to facial paralysis distress and stroke fear. Diagnosis is clinical, not requiring imaging. Key differentiators from stroke include: Bell's palsy causes peripheral paralysis affecting the entire half of the face (including eye and forehead), while stroke causes central paralysis affecting only the lower two-thirds. Bell's palsy patients have isolated facial paralysis without limb weakness and often experience prodromal paresthesia 24-48 hours before paralysis. Treatment focuses on two evidence-based interventions: eye protection (lubricating drops during day, eye patches at night) to prevent corneal complications, and corticosteroids (prednisone 60mg daily for 5-7 days, then tapering) started within 48 hours to reduce nerve inflammation. Antivirals lack proven efficacy per Cochrane meta-analysis. Rehabilitation through physical and speech therapy may accelerate recovery when accessible.

Corticosteroid treatment typically starts at high doses (prednisone 40mg) and is gradually tapered over several weeks. Patients should not fear the initial high dose as it is necessary for effective treatment. Follow-up appointments are essential for dosage adjustment. Bell's Palsy can occur in children and typically responds well with faster recovery. Treatment includes corticosteroids prescribed by a doctor and regular facial exercises.

Treatment varies by etiology: corticosteroids (prednisone 1mg/kg/day for 15-21 days) are the gold standard for Bell's palsy and zoster oticus, improving recovery speed; antivirals may be added for viral etiologies. For traumatic cases without nerve section, corticosteroids improve outcomes. Complete nerve section requires surgical repair (neurorrhaphy, nerve grafting) if proximal nerve function is preserved. Vitamin B complex provides neuroprotection in incomplete injuries but cannot regenerate severed nerves. Ocular protection is critical—patients lose blink reflex and lacrimal secretion, risking corneal damage requiring artificial tears and eye protection. Rehabilitation begins 10-15 days post-injury and continues 6-12 months. Diabetic facial palsy requires glycemic control rather than corticosteroids.

Early short-term oral glucocorticoid treatment is the mainstay of pharmacologic therapy for Bell's palsy. All new-onset patients should receive prednisone 60-80 mg daily for one week, starting within three days of symptom onset. A one-week regimen without tapering is preferred. Common side effects include sleep disturbances, mood changes, and dyspepsia; hyperglycemia requires caution in diabetic patients. Antiviral therapy (valacyclovir 1000 mg TID for 7 days or acyclovir 400 mg QID for 10 days) is indicated only for severe cases (House-Brackmann grade IV+). While antivirals show limited evidence of benefit, they carry risks including headaches and potential psychiatric side effects in elderly patients. Glucocorticoids alone are appropriate for milder symptoms.

Electrodiagnostic tests use electrical current to assess facial nerve function through four main tests: Minimal Nerve Excitability Test (minimum current for muscle twitching, 3.5mA difference indicates degeneration), Maximum Stimulation Test (compares maximum muscle movement), Electromyography (EMG) (measures electrical activity in orbicularis oculi/oris muscles showing biphasic/triphasic potentials normally, fibrillation potentials at 14-21 days indicate degeneration, polyphasic reinnervation potentials at 6-12 weeks indicate regeneration), and Electroneuronography (quantifies degeneration percentage). These tests differentiate neuropraxia from degeneration, guide surgical decisions (nerve grafting, muscle transplantation), and predict prognosis. Patients with 90% degeneration within 14 days have poor prognosis. Testing is performed 2-3 days post-injury for excitability tests and 4-21 days post-complete paralysis for EMG.

Electrophysiological testing in facial nerve palsy includes: (1) Electrodiagnostic testing - measures the degree of nerve damage; (2) Electroneuronography - assesses nerve regeneration; (3) Electromyography - evaluates muscle activity; (4) Electrodiagnostic testing - measures the degree of nerve damage. These tests help determine the severity of nerve damage, predict recovery, and guide treatment decisions.

Electrodiagnostic tests including minimum nerve excitability test, maximum stimulation test, electroneuronography, and electromyography are essential diagnostic tools used to differentiate between neuropraxia (reversible nerve dysfunction) and nerve degeneration (irreversible damage), thereby determining prognosis and recovery potential in facial nerve disorders.

The House-Brackmann grading system classifies facial nerve function: Grade 1 (normal), Grade 2 (mild dysfunction), Grade 3 (moderate dysfunction), Grade 4 (severe dysfunction), Grade 5 (severe dysfunction with asymmetry at rest), Grade 6 (total paralysis). Electrophysiological assessment includes: (1) Electroneuronography (ENoG) - measures compound muscle action potentials to determine degeneration percentage. (2) Electromyography (EMG) - assesses muscle electrical activity. (3) Stapedial reflex testing - evaluates acoustic reflex. (4) Taste testing - assesses chorda tympani function. These tests help localize lesions and predict prognosis.

Electroneuronography (ENoG) interpretation for facial nerve palsy: >90% degeneration indicates poor prognosis and may indicate need for surgical decompression. ENoG should be performed before day 14 to avoid false negatives. ENoG is not indicated for Bell's palsy (neuropraxia). Lesion types include: neuropraxia (myelin damage, normal ENoG), axonotmesis (axon damage, reduced ENoG), and neurotmesis (complete nerve transection, absent ENoG). Clinical assessment includes House-Brackmann grading, Chow test (lacrimation), taste testing, and stapedial reflex testing. These tests help localize the lesion and guide treatment decisions.